Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Unknown 2Completed 2Recruiting 1

Sponsor Class

OTHER 32NIH 12INDUSTRY 5NETWORK 4OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 107Neoplasms 80Colorectal Neoplasms 54Uterine Cervical Neoplasms 29Stomach Neoplasms 29Lung Neoplasms 27Rectal Neoplasms 25Prostatic Neoplasms 25Colonic Neoplasms 24Polycystic Ovary Syndrome 22Pancreatic Neoplasms 22Head and Neck Neoplasms 17Endometrial Neoplasms 17Carcinoma, Non-Small-Cell Lung 16Carcinoma, Hepatocellular 16Pain 15Neoplasm Metastasis 15Motor Activity 15Esophageal Neoplasms 15Ovarian Neoplasms 13Urinary Bladder Neoplasms 11Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Pain, Postoperative 10Melanoma 10Thyroid Neoplasms 9Pilonidal Sinus 9Multiple Myeloma 9Gastrointestinal Neoplasms 9Sarcopenia 8

Interventions

eribulin 1camrelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × OTHER_GOV × Drug-Related Side Effects and Adverse Reactions × Clear all
NCT05355168 2024-12-31

Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma

Anhui Provincial Hospital

Phase 2 Completed
35 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Drug-Related Side Effects and Adverse Reactions

NCT02864030 2021-03-04

PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment

Oncologia Medica dell'Ospedale Fatebenefratelli

Phase 4 Completed
200 enrolled
Breast

Breast Neoplasms, Neurotoxicity Syndromes, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡